NASDAQ$MDGL
Madrigal Pharmaceuticals Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Madrigal reported Q4 2022 financial results and provided corporate updates.
Madrigal Pharmaceuticals reported positive Phase 3 MAESTRO-NASH study results in Q4 2022, positioning the company for a new drug application filing in the first half of 2023. The company's year-end cash, cash equivalents, and marketable securities totaled $358.8 million.
- Positive Phase 3 MAESTRO-NASH study results were reported in December 2022.
- Madrigal is preparing for a resmetirom new drug application filing in the first half of 2023.
- Year-end cash, cash equivalents, and marketable securities were reported at $358.8 million.
- The company is advancing regulatory filing preparations and prelaunch market development programs.
Headline financials
Revenue & EPS history
Madrigal · Revenue · Quarterly
$311M
Forward guidance
Madrigal is on track to file its NDA for resmetirom in the first half of 2023 supported by positive Phase 3 biopsy results and ongoing outcomes studies.
Tailwinds
- NDA filing for resmetirom is on track for the first half of 2023.
- Filing is supported by positive Phase 3 biopsy results.
- Standalone Phase 3 safety study supports the filing.
- Two ongoing outcomes studies are designed to verify clinical benefit.
- MAESTRO-NASH outcomes portion is expected to be fully enrolled prior to NDA filing.
Headwinds
- Potential regulatory delays or rejections.
- Risks associated with meeting the objectives of Madrigal’s clinical studies.
- Any delays or failures in enrollment, and the occurrence of adverse safety events.
- Market demand for and acceptance of our products.
- The potential inability to raise sufficient capital to fund ongoing operations as currently planned or to obtain financings on terms similar to those arranged in the past.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-0.6%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+7.8%
Avg return
30 days after
45%
29 / 65 earnings
Positive
+48.0%
Q3 2024
Best reaction
-23.3%
Q4 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -1.2% | -3.2% | |
| Q4 2025 | -11.1% | -10.5% | -10.2% | |
| Q3 2025 | +7.8% | +18.7% | +42.2% | |
| Q1 2025 | -1.9% | -11.6% | -17.6% | |
| Q4 2024 | +15.0% | +1.3% | +5.9% | |
| Q3 2024 | +48.0% | +56.4% | +52.0% | |
| Q2 2024 | -8.6% | -9.2% | -8.5% | |
| Q1 2024 | -11.7% | -12.9% | +2.5% | |
| Q4 2023 | -1.5% | +2.8% | +11.4% | |
| Q3 2023 | +3.6% | -5.5% | +61.1% | |
| Q2 2023 | -6.0% | -4.5% | +6.4% | |
| Q1 2023 | -5.4% | -5.2% | -12.8% | |
| Q4 2022 | -5.4% | -7.1% | -19.6% | |
| Q3 2022 | -6.7% | -10.1% | +12.8% | |
| Q2 2022 | +22.8% | +12.1% | +10.8% | |
| Q1 2022 | -0.2% | +1.8% | +15.0% | |
| Q4 2021 | +7.9% | +13.1% | +9.2% | |
| Q3 2021 | -0.5% | -1.6% | -16.6% | |
| Q2 2021 | +7.5% | +0.8% | -4.5% | |
| Q1 2021 | +0.7% | +2.3% | -22.0% | |
| Q4 2020 | -1.3% | -6.9% | -5.3% | |
| Q3 2020 | -6.8% | -2.2% | -10.9% | |
| Q2 2020 | -1.1% | -2.2% | +2.3% | |
| Q1 2020 | +2.9% | +25.1% | +27.6% | |
| Q4 2019 | -2.5% | +2.6% | -19.7% | |
| Q3 2019 | +0.1% | +7.9% | +22.1% | |
| Q2 2019 | +2.0% | +2.0% | +9.8% | |
| Q1 2019 | +0.2% | -3.4% | -8.0% | |
| Q4 2018 | -2.4% | +3.1% | -6.9% | |
| Q3 2018 | +5.2% | -7.8% | -39.7% | |
| Q2 2018 | -1.0% | -5.9% | -11.0% | |
| Q1 2018 | -0.0% | +2.2% | +138.3% | |
| Q4 2017 | -16.4% | -20.4% | -15.8% | |
| Q3 2017 | -0.2% | -5.7% | +84.7% | |
| Q2 2017 | -0.8% | +1.7% | +13.5% | |
| Q1 2017 | +2.1% | +4.5% | -0.3% | |
| Q4 2016 | -2.2% | -4.9% | +6.8% | |
| Q3 2016 | +5.3% | +2.4% | -1.4% | |
| Q2 2016 | +3.8% | +11.5% | +1.9% | |
| Q1 2016 | +10.5% | — | — | |
| Q4 2015 | -23.3% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | -3.4% | — | — | |
| Q1 2015 | +1.3% | — | — | |
| Q4 2014 | -6.1% | — | — | |
| Q3 2014 | +10.6% | — | — | |
| Q2 2014 | +0.5% | — | — | |
| Q1 2014 | +3.3% | — | — | |
| Q4 2013 | -10.1% | — | — | |
| Q3 2013 | +0.9% | — | — | |
| Q2 2013 | -4.2% | — | — | |
| Q1 2013 | +2.5% | — | — | |
| Q4 2012 | -5.0% | — | — | |
| Q3 2012 | -5.2% | — | — | |
| Q2 2012 | +0.3% | — | — | |
| Q1 2012 | -11.2% | — | — | |
| Q4 2011 | +0.2% | — | — | |
| Q4 2009 | +0.2% | — | — | |
| Q3 2011 | +4.4% | — | — | |
| Q2 2011 | -10.1% | — | — | |
| Q4 2010 | -10.1% | — | — | |
| Q1 2011 | +1.6% | — | — | |
| Q3 2010 | -6.1% | — | — | |
| Q2 2010 | -5.6% | — | — | |
| Q1 2010 | -16.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro